logo-loader
RNS
viewArix Bioscience PLC

Arix Bioscience Plc - Notice of Results

Arix Bioscience plc

Notice of Results

(“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its annual results for the year ended , on Tuesday ., :LONDON27 February 2020Arix Bioscience plc31 December 201910 March 2020

A presentation for analysts will be held on the same day at in and a webcast of the presentation will be available on the Company's investor relations website at .12:15pm GMTLondonhttps://arixbioscience.com/investor-relations/results-centre

[ENDS]

Enquiries

For more information on Arix, please contact:

, Head of Investor Relations +44 (0) 20 7290 1072Arix Bioscience plc


Charlotte Parry[email protected]

Mary Clark, , T: +44 (0) 20 3950 9144Optimum Strategic Communications


Supriya MathurShabnam Bashir[email protected]

AboutArix Bioscience plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.Arix Bioscience plc

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com

Quick facts: Arix Bioscience PLC

Price: 95.5

Market: LSE
Market Cap: £129.45 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018